---
title: 'Oligometastatic non-small cell lung cancer: Impact of local and contemporary
  systemic treatment approaches on clinical outcome'
date: '2024-09-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39319506/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240925194808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct
  but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation
  with local ablative therapy (LAT). However, evidence regarding the optimal choice
  of multimodal treatment approaches is lacking, in particular with respect to the
  integration of immunotherapy. This real-world study identified 218 patients with
  OMD NSCLC (2004-2023, prespecified criteria: ≤5 metastases in ≤2 organ systems)
  from ...'
disable_comments: true
---
Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real-world study identified 218 patients with OMD NSCLC (2004-2023, prespecified criteria: ≤5 metastases in ≤2 organ systems) from ...